Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVA-TTR: Sacubitril/Valsartan in ATTR-CM with HFrEF
NCT06712030Phase 3Not yet recruiting
- Sponsor
- Hospital Universitario Puerta de Hierro Majadahonda
- Start
- Jan 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacubitril + valsartan in transthyretin amyloid cardiomyopathy (ATTR-CM) (2 arms), sponsored by Hospital Universitario Puerta de Hierro Majadahonda. Primary endpoint: Left Ventricular Ejection Fraction at 12 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT06712030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712030.